Genomed
- Company typePublic
- Founded2008
- HeadquartersWarszawa, Poland
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
Genomed firmographics
Firmographics- Name
- Genomed
- Legal name
- Genomed S.A.
- Website
- https://genomed.pl
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Genomed industry classification
Industry- Product category
- Clinical Genetic Diagnostics and NGS Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where Genomed is headquartered
LocationHeadquarters
- HQ city
- Warszawa
- HQ country
- Poland
- HQ region
- Europe
Offices2 records
Markets served
Genomed business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Genetic Testing Services (B2C): Direct-to-patient genetic testing services through the NZOZ Genomed health centre including prenatal tests (SANCO, SANCO RHD, NIFTY), whole genome sequencing, whole exome sequencing, carrier screening (Parento), infant screening (INFANO), and disease-specific panels (oncology, cardiology, neurology, etc.). Tests are ordered online or in-person with genetic counselling included.
- DNA Sequencing Services for Research (B2B): DNA sequencing, analysis, and synthesis services provided to over 200 scientific centres, biotechnology companies, and medical institutions. Includes NGS sequencing, bioinformatics analysis, de novo genome sequencing, exome sequencing, and metagenome analysis.
- POLGENOM Database Licensing: Commercial licensing of the Polish Reference Genome Database to research institutions, pharmaceutical companies, and clinical studies. The database is available at www.polgenom.pl.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Whole Genome Sequencing with diagnostic analysis |
| One time/ perpetual license | Pay-as-you-go | SANCO Non-Invasive Prenatal Test |
| One time/ perpetual license | Pay-as-you-go | SANCO RHD Test - fetal RhD status assessment |
| One time/ perpetual license | Pay-as-you-go | NIFTY Non-Invasive Prenatal Test |
| One time/ perpetual license | Pay-as-you-go | INFANO - genetic screening test for infants |
| Unit Pricing | Pay-as-you-go | Parento - carrier screening test for parents-to-be |
| One time/ perpetual license | Pay-as-you-go | Silver-Russell Syndrome genetic test |
| One time/ perpetual license | Pay-as-you-go | Clinical Exome and Clinical Exome MAXIMUM |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Genomed product offering
Product offeringCore offering
Genomed operates a genetic diagnostics and personalized medicine platform that delivers NGS-based tests (WGS, WES, NIPT), carrier and infant screening panels, and disease-specific genetic panels to individual patients through its NZOZ Genomed clinic and a ~300-clinic partner network. It separately provides B2B DNA sequencing, bioinformatics, and oligonucleotide synthesis services to over 200 scientific and biotech customers, and licenses the POLGENOM Polish population reference genome database to researchers and pharmaceutical firms. Revenue is generated from per-test diagnostic fees, professional sequencing service fees, and database licensing.
Product overview
Genomed is a Polish genetic diagnostics company offering a comprehensive portfolio of genetic testing services centered on Next Generation Sequencing (NGS) technology. The core offerings include SANCO prenatal tests (non-invasive prenatal screening), Whole Exome Sequencing (WES), and Whole Genome Sequencing (GS) services. The product line spans preconception carrier screening (Parento), infant screening (INFANO), cancer predisposition testing (ONKO-MAX), and disease-specific tests. Supporting services include the Polgenom Polish Reference Genome Database for population-specific analysis and genetic counseling. The company operates as a single unified diagnostic service platform with multiple testing options and sub-brands for different market segments (clinical, research, personal genomics).
Differentiator
Problem solved
Functional benefit
Brands
- SANCO: Non-invasive prenatal genetic test (NIPT) that analyzes cell-free fetal DNA from maternal blood to screen for chromosomal conditions including trisomy 21 (Down syndrome) and determines fetal RhD status.
- Polgenom
- Parento
- Infano
- Clinical WES
Products and services
- SANCO Non-Invasive Prenatal Test Non-invasive prenatal genetic test (NIPT) that analyzes cell-free fetal DNA from maternal blood to screen for chromosomal conditions including trisomy 21 (Down syndrome), all 23 pairs of chromosomes, sex chromosomes, deletion and duplication syndromes from 7 Mbp, uniparental disomy risk, and early cancer detection. >99.5% accuracy with results in 5 business days.
- SANCO RHD Test Non-invasive prenatal test that determines fetal RhD status from maternal blood to guide immunoglobulin prophylaxis during pregnancy.
- NIFTY Non-Invasive Prenatal Test NIPT offered to pregnant women via NZOZ Genomed and partner clinics with 9-business-day turnaround.
- Clinical Whole Exome Sequencing (WES) Sequencing of protein-coding regions covering approximately 85% of genetic variants responsible for genetic diseases, with analysis of copy number variants (CNVs) and clinically relevant non-coding variants. Available as Clinical Exome or Clinical Exome MAXIMUM.
- Whole Genome Sequencing (WGS) Complete genome sequencing service with diagnostic analysis of over 5,000 genes associated with genetic disorders, including pharmacogenomic variants and nutrigenomic dietary recommendations.
- Parento Carrier Screening Test Preconception carrier screening test for couples planning children, analyzing over 1,700 genes for more than 1,300 diseases including spinal muscular atrophy, cystic fibrosis, fragile X syndrome, and congenital adrenal hyperplasia, using NGS combined with MLPA and RFLP techniques.
- INFANO Genetic Screening for Infants Genetic screening test for infants and babies detecting over 70 diseases of genetic origin where prevention or therapy can halt development or prevent complications, covering metabolic, neurological, immunodeficiency, blood, eye, and ACMG-essential genes for childhood cancers and cardiovascular disorders.
- ONKO-MAX Cancer Predisposition Panel Comprehensive cancer predisposition genetic test analyzing over 90 genes responsible for hereditary cancer, identifying pathogenic variants correlated with cancer risk and supporting personalised prevention plans.
- NGS Service Portfolio for Research & Biotech Next-Generation Sequencing services for research and biotech market including de novo sequencing of prokaryotic and eukaryotic genomes, exome sequencing, resequencing of genome fragments and amplicons, transcriptome sequencing, and metagenome sequencing and analysis (16S RNA, ITS).
- Oligonucleotide Synthesis Services Oligonucleotide (DNA fragment) synthesis services for research laboratories and biotechnology customers.
- POLGENOM - Polish Reference Genome Database The only genomic database for the Polish population, unique internationally. Commercially licensed to research institutions, pharmaceutical companies, and clinical studies as a control group for population genetic studies and reference for genome analysis in diagnostics and personalised medicine.
- Genetic Counseling Service Clinical genetic counseling services provided by certified specialists for pre- and post-test consultation at NZOZ Genomed in Warsaw.
- DNA Sequence Analysis Services DNA sequence analysis and bioinformatics services provided to research and biotech customers.
Quantifiable outcome
- >99.5% test accuracy for the SANCO Non-Invasive Prenatal Test
- +4 more outcomes
Companies that use Genomed
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Genomed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Genomed partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- International Institute of Molecular and Cell Biology in WarsawcoreConsortium partner in the POLGENOM project 'Polish Reference Genome for Genomic Diagnostics and Personalised Medicine', co-financed by the Polish National Centre for Research and Development within the INNOTECH programme.
- Mossakowski Medical Research Centre of the Polish Academy of SciencecoreConsortium partner in the POLGENOM project for creating the Polish Reference Genome Database.
- 24godziny Sp. z o. o.coreConsortium partner in the POLGENOM project for creating the Polish Reference Genome Database.
- Instytut Matki i Dziecka (Institute of Mother and Child, Warsaw)coreGenomed performed genetic testing for the national cystic fibrosis newborn screening programme on behalf of the institute from 2010-2012, approved by the Polish Ministry of Health. Active scientific cooperation with the institute's Department of Genetics.
- Polsko-Japońska Wyższa Szkoła Technik Komputerowych (Polish-Japanese Academy of Information Technology)coreIn October 2010, Genomed partnered with this institution and Centrum Onkologii to open the first interdisciplinary doctoral programme 'Bioinformatyka' in Poland, focused on personalised medicine and human genome analysis.
- Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Gliwicach (Maria Skłodowska-Curie Oncology Centre – Institute, Gliwice)corePartner in the interdisciplinary doctoral programme 'Bioinformatyka'. Scientific cooperation in population genetics projects.
- Diagnostyka SAminorBlood collection centre network. Venous blood samples from children under 10 can be collected at selected Diagnostyka network points based on a requisition issued by Genomed.
- European Molecular Quality Network (EMQN)coreGenomed participates in EMQN's external quality assessment schemes for genetic testing, achieving highest scores across multiple years and disease categories.
- Polish Society of Human Genetics - Network of Reference LaboratoriescoreNZOZ Genomed belongs to the Network of Reference Laboratories of the Polish Society of Human Genetics, covering diagnostics of over 20 genetic conditions.
Scale indicators10 records
Recent moves9 records
Expansion highlights5 records
Genomed competitors and assessment
Company assessmentBroad incumbents
- Myriad Genetics: Established US clinical genetics company spanning hereditary cancer (BRCA), prenatal, pharmacogenomic, and mental health testing. Comparable as a broad incumbent across Genomed's hereditary cancer (ONKO-MAX), NIPT, and pharmacogenomic offerings, but with much wider geographic and portfolio reach.
- Eurofins Genomics: European genomics services provider offering DNA sequencing, oligonucleotide synthesis, and bioinformatics to research and biotech customers. Highly comparable to Genomed's B2B sequencing and oligonucleotide synthesis arm serving 200+ scientific centres and biotech companies.
- Synlab: Europe's largest medical diagnostics services group with extensive clinical laboratory networks across CEE and Western Europe. Comparable to Genomed as a regional clinical laboratory operator, though Synlab is far broader (routine clinical chemistry, pathology) while Genomed focuses on advanced genetic testing.
- Invitae (Labcorp): US-based clinical genetics testing company (now part of Labcorp) offering comprehensive hereditary disease, reproductive, and somatic NGS panels at scale. Comparable as a broad incumbent in clinical NGS diagnostics where Genomed competes on hereditary cancer and reproductive panels.
Direct peers
- Centogene: European clinical genetics and genomics laboratory focused on rare hereditary diseases and biomarker testing using NGS. Comparable to Genomed as a European specialty genetics lab combining WES/WGS diagnostics, carrier screening, prenatal testing, and reference-lab services to clinicians and pharma.
- Natera: US-listed specialty genetics company best known for non-invasive prenatal testing (Panorama) and reproductive/oncology NGS panels. Closely comparable to Genomed on NIPT product (SANCO), reproductive carrier screening (Parento), and hereditary cancer panels (ONKO-MAX).
- Blueprint Genetics (Quest Diagnostics): NGS-based clinical genetic diagnostics lab specializing in hereditary disease panels and rare-disease whole exome sequencing. Comparable to Genomed's Clinical WES, disease-specific panels, and reference-laboratory positioning for complex inherited disorders.
Regional players
- Medicover: Major private healthcare provider in Poland and CEE operating clinics, hospitals, and diagnostic services. Comparable as a regional private healthcare player overlapping with Genomed on clinical diagnostics and patient-facing genetic counselling pathways in Poland.
- Diagnostyka SA: Poland's largest medical laboratory network, and a current sample-collection channel partner for Genomed. Comparable as a domestic Polish diagnostics provider with overlapping phlebotomy/sample collection infrastructure and overlapping clinical-laboratory services.
Emerging players
- Macrogen: Asia-based genomics services company providing NGS sequencing, clinical diagnostics, and microarray services globally. Comparable to Genomed's B2B sequencing services portfolio (de novo sequencing, exome, metagenome) for research and clinical customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Genomed social profiles
Digital presenceGenomed compliance and trust
Trust signalCompliance6 records
Genomed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomed leadership team
Management profileNumber of profiles
Profiles2 records
Genomed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomed
What does Genomed do?
Genomed operates a genetic diagnostics and personalized medicine platform that delivers NGS-based tests (WGS, WES, NIPT), carrier and infant screening panels, and disease-specific genetic panels to individual patients through its NZOZ Genomed clinic and a ~300-clinic partner network. It separately provides B2B DNA sequencing, bioinformatics, and oligonucleotide synthesis services to over 200 scientific and biotech customers, and licenses the POLGENOM Polish population reference genome database to researchers and pharmaceutical firms. Revenue is generated from per-test diagnostic fees, professional sequencing service fees, and database licensing.
Is Genomed a public or private company?
Genomed is a public company. It is classified as public and is currently operating.
When was Genomed founded?
Genomed was founded in 2008. It employs 11 to 50 people.
Where is Genomed based?
Genomed is headquartered in Warszawa, Poland, in the Europe region.
How does Genomed make money?
Three revenue lines are on record. Genetic Testing Services (B2C) is the primary driver. The others are DNA Sequencing Services for Research (B2B) and POLGENOM Database Licensing.
Who are Genomed's main competitors?
Broad incumbents on record are Myriad Genetics, Eurofins Genomics, Synlab and Invitae (Labcorp). Direct peers are Centogene, Natera and Blueprint Genetics (Quest Diagnostics). Regional players are Medicover and Diagnostyka SA. Macrogen is listed as an emerging player.
Does Genomed have an API?
No public API is recorded for Genomed.
What industry is Genomed in?
Genomed's product category is Clinical Genetic Diagnostics and NGS Services. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 8071.